GLOW with KPV added — a community four-peptide blend marketed for inflammatory skin conditions and advanced recovery. The combination has no published human evidence and is component-extrapolated.
No published clinical trial exists for the KLOW combination in any species. Every claim about KLOW is extrapolated from individual-component literature. The four peptides have not been studied together in humans, and there is no published PK, stability, or compatibility data for the four-component blend.
KLOW is GLOW + KPV — the same three-peptide skin/hair/healing base (BPC-157, TB-500, GHK-Cu) with the tripeptide KPV (Lys-Pro-Val) added as a fourth component.
The rationale: GLOW handles regeneration and collagen, while KPV is community-marketed as an anti-inflammatory adjunct based on its NF-κB-pathway literature. KLOW is positioned for inflammatory skin conditions (eczema, psoriasis, rosacea, autoimmune flares) and advanced recovery protocols where users want both regenerative and anti-inflammatory components in one vial.
Components not individually FDA approved; the KLOW combination has no IND/NDA. WADA: BPC-157 prohibited under S0; TB-500 prohibited under S2.3. KPV has never been on the FDA 503A bulks list (anomaly vs the BPC/TB/GHK-Cu timeline). In April 2026 FDA procedurally removed BPC-157, TB-500, and GHK-Cu from compounding Category 2 because original nominators withdrew — not safety clearance, not authorization to compound. PCAC will review BPC-157 and TB-500 on July 23, 2026 and GHK-Cu in February 2027 for §503A bulks-list inclusion. None is legally compoundable today. DoD/OPSS specifically warns service members against BPC-157 and any blend containing it.
Angiogenesis, cell migration, and collagen synthesis — the regenerative foundation. See the GLOW guide for full detail.
Tripeptide derived from the C-terminus of α-MSH. KPV inhibits NF-κB signaling in cell-based assays and reduces TNF-α / IL-1β / IL-6 in inflammatory cell models. Note: KPV lacks the His-Phe-Arg-Trp pharmacophore that drives mast-cell stabilization in the parent α-MSH literature — that effect should not be assumed for the tripeptide. Mast-cell-stabilization claims in community marketing are α-MSH-parent inference, not KPV-specific data.
The mechanistic cartoon — KPV quieting inflammation, GLOW components driving regeneration — is internally consistent and is the basis for the inflammatory-skin pitch. It has not been demonstrated in any peer-reviewed combination study. Whether the four peptides combine additively, synergistically, or with cross-interference is empirically unknown.
| Benefit | Evidence |
|---|---|
| Eczema / atopic dermatitis | Mechanistic: KPV NF-κB pathway modulation in cell-based assays; GHK-Cu supports barrier repair (topical evidence). No clinical study of KLOW or any KLOW-component combination in eczema. |
| Psoriasis | Mechanistic: KPV's NF-κB inhibition is upstream of the Th17 driver in cell-based assays. "Directly targets the Th17 driver" overstates — KPV's effect on Th17-axis cytokines in psoriasis specifically has not been demonstrated in patients. |
| Rosacea | Anecdotal; no published study of KLOW or any combination component in rosacea. |
| Chronic wound healing | Component evidence: BPC-157 rodent wound models; full-Tβ4 keratinocyte migration (Malinda 1999, PMID 10469335); GHK-Cu Iamin Gel diabetic ulcer trial (Mulder 1994, PMID 17147644). KPV antimicrobial activity is in vitro. No combination study. |
| Post-procedure recovery | Community/clinical convention; no published RCT. |
| Scalp / hair | Mechanistic only — see GLOW guide for the underlying full-Tβ4 vs heptapeptide and Pickart-group GHK-Cu hair literature. No alopecia-areata RCT for KLOW or any component combination. |
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeDuring active flares (eczema, psoriasis plaques, autoimmune skin reactions), dose daily for 2–4 weeks, then taper to 3×/week for 4–8 weeks as symptoms resolve.
Some suppliers sell a KLOW-style topical cream. Important: only GHK-Cu has meaningful skin permeation (and even that is hydrophilicity-limited per Hostynek 2011 and Ogórek 2025); BPC-157, TB-500, and KPV are essentially inert at the stratum corneum. Topical "KLOW" is functionally a topical GHK-Cu preparation. Apply 1–2×/day to affected skin if used.
KLOW is typically supplied as a pre-mixed blend (exact ratios vary by supplier). Like GLOW, the copper content gives it a blue tint.
Typical KLOW vial contains 10 mg BPC-157 + 10 mg TB-500 + 50 mg GHK-Cu + 10 mg KPV (80 mg total). With 2 mL BAC water = 40 mg/mL total peptide (5 mg/mL BPC, 5 mg/mL TB, 25 mg/mL GHK-Cu, 5 mg/mL KPV). A typical 0.05–0.10 mL injection delivers BPC 250–500 mcg / TB 250–500 mcg / GHK-Cu 1.25–2.5 mg / KPV 250–500 mcg. Confirm against your specific vial's label — supplier ratios vary.
Copper-load disclosure: KLOW delivers more elemental copper per session than monotherapy GHK-Cu (50 mg GHK-Cu / 80 mg vial). Cumulative copper exposure across a 4-week flare protocol can reach 35–50 mg total — for context, the NIH oral upper limit is 10 mg/day. Long-term injectable copper safety has not been formally characterized; periodic ceruloplasmin / serum copper monitoring is reasonable for users on extended high-dose regimens.
All compounds share one vial. Edit any amount or change the BPC-157 dose — the other doses scale by ratio.
Insulin syringe — 100 units = 1 mL
Free account. Saves your reconstitution + schedules doses + tracks every vial.
Dosing cheat sheet, reconstitution reference, and cycle planning — delivered to your inbox.
Side effects are the union of GLOW + KPV. KPV is remarkably well-tolerated and adds minimal risk to the GLOW profile.
Adverse-effect profile is inferred from individual-component literature; no published safety data exists for the KLOW combination. Long-term safety of repeated injectable copper loading has not been formally characterized.
Looking for KLOW (BPC-157 + TB-500 + GHK-Cu + KPV)? We recommend NextGen Peptides — third-party tested, fast shipping, and trusted by the StackTrax community.
10% off with code
Exclusive StackTrax discount
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeKLOW is a community four-peptide blend of BPC-157, TB-500, GHK-Cu, and KPV. It is GLOW (BPC + TB + GHK-Cu) with the tripeptide KPV added as a fourth component. It is positioned for inflammatory skin conditions (eczema, psoriasis, rosacea, autoimmune flares) and advanced recovery protocols where users want both regenerative and anti-inflammatory components in one vial.
The rationale is that GLOW handles regeneration and collagen while KPV is community-marketed as an anti-inflammatory adjunct based on its NF-kB-pathway literature. The mechanistic cartoon (KPV quieting inflammation, GLOW components driving regeneration) is internally consistent but has not been demonstrated in any peer-reviewed combination study. Whether the four peptides combine additively, synergistically, or with cross-interference is empirically unknown.
No. No published clinical trial of the KLOW combination exists in any species. Every claim is extrapolated from individual-component literature. There is no published PK, stability, or compatibility data for the four-component blend, and no peer-reviewed study of KLOW or any KLOW-component combination in eczema, psoriasis, or rosacea.
Community protocols use one injection per session, 3 to 5 times per week subcutaneously for 4 to 8 weeks of active flare, then an 8 to 12 week maintenance phase. A typical vial contains 10 mg BPC-157 + 10 mg TB-500 + 50 mg GHK-Cu + 10 mg KPV (80 mg total). With 2 mL bacteriostatic water, a 0.05 to 0.10 mL injection delivers roughly 250 to 500 mcg each of BPC, TB, and KPV plus 1.25 to 2.5 mg GHK-Cu.
KLOW is GLOW plus KPV. The three-peptide GLOW base (BPC-157, TB-500, GHK-Cu) handles angiogenesis, cell migration, and collagen synthesis. KPV is added as an NF-kB pathway modulator to lean the blend toward inflammatory skin conditions. The trade-off is a heavier per-session copper load, since the typical KLOW vial contains 50 mg GHK-Cu.
The side effect profile is the union of GLOW and KPV: injection site reactions, mild fatigue early on, and transient injection-site pigmentation from GHK-Cu. KPV adds minimal risk to the GLOW profile. KLOW is contraindicated in Wilson's disease, active hepatic copper overload, patients on copper chelators (penicillamine, trientine), active malignancy, and pregnancy or breastfeeding. Cumulative copper exposure across a 4-week flare protocol can reach 35 to 50 mg total, well above the 10 mg/day NIH oral upper limit, and long-term injectable copper safety has not been formally characterized.
Components are not individually FDA approved and the KLOW combination has no IND/NDA. WADA prohibits BPC-157 under S0 and TB-500 under S2.3 at all times, with no TUE pathway, so KLOW is prohibited for athletes via those components. DoD/OPSS specifically warns service members against BPC-157 and any blend containing it. In April 2026 FDA procedurally removed BPC-157, TB-500, and GHK-Cu from compounding Category 2 because original nominators withdrew, which is not safety clearance and not authorization to compound.
Disclaimer: This guide is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The compounds discussed are not FDA approved for human use. Always consult a qualified healthcare provider before starting any new supplement or peptide protocol. StackTrax does not sell peptides or supplements directly — purchase links go to third-party vendors. StackTrax is not responsible for the products, quality, or business practices of any third-party vendor. This page contains affiliate links — StackTrax may earn a commission on purchases at no extra cost to you.
© 2026 StackTrax, LLC. All rights reserved.
StackTrax guides cover peptides and compounds that are not FDA-approved for the uses discussed. The dosing, reconstitution, and safety information is compiled from published research and community protocols for educational purposes only.
Before using any compound mentioned here, consult a qualified healthcare provider. StackTrax does not sell, prescribe, or recommend these substances for personal use.
These pages also contain affiliate links. We may earn a commission on purchases at no extra cost to you — this never changes our editorial recommendations.